SHARPE·IQStart free
Menu
TodayResearchEarningsToolsPricingSign in
LRMR reported Third Quarter 2026 results. The price and volatility reaction is pending.
LRMRearnings

Earnings reactions, page 2

Larimar Therapeutics, Inc. (LRMR) Q3 FY2026 earnings

November 16, 2026 · SharpeIQ Research Desk

Reported results

  • The Company reported a net loss of $31.1 million, or $0.29 per common share, for the third quarter of 2026.
  • Research and development expenses were $25.9 million for the third quarter of 2026.
  • General and administrative expenses were $6.5 million in the third quarter of 2026.
  • As of September 30, 2026, the Company had cash, cash equivalents and marketable securities totaling $128.7 million.
  • The Company reported a net loss for the first nine months of 2026 of $93.5 million, or $0.90 per common share.

Guidance

  • The Company projects its cash runway into late Q2 2027.
  • BLA Submission Acceptance: Early 2027
  • Open Label Study Safety Update: Q1 2027
  • U.S. Approval: Mid-2027
  • Obtaining & Monetizing the Rare Pediatric Disease Priority Review Voucher: Mid-2027, if approved
  • U.S. Launch: Targeting Q3 2027 launch, if approved

Price and volatility reaction

Source

The figures above come from the earnings release the company filed with the SEC on 2026-11-16 (8-K, Item 2.02). Read the original filing on sec.gov.

See this live in SharpeIQ

IV rank, historical IV and the single-ticker tools. The scanner and AI research are paid plans.

Open IV Rank →